Shares of vaccine makers Moderna (MRNA), Novavax (NVAX), and Pfizer (PFE) extended their recent declines in premarket trading on Friday, following President-elect Donald Trump\u2019s announcement that he intends to appoint Robert F. Kennedy Jr. as Secretary of Health and Human Services (HHS). The news sent ripples through the healthcare sector, with Moderna and Novavax stocks each down more than 30% over the past month as uncertainty grows regarding future vaccine policies.<\/p>\n\n\n\n
The slide continued after Trump confirmed the nomination on X (formerly Twitter) following Thursday\u2019s market close. His announcement included a statement that \u201cthe safety and health of all Americans\u201d would be a priority, emphasizing HHS\u2019s role in protecting the public from \u201charmful chemicals, pollutants, pesticides, pharmaceutical products, and food additives.\u201d This message, along with Trump\u2019s comments during a recent rally where he promised to let Kennedy \u201cgo wild\u201d on healthcare reform, has fueled concerns in the market about a potential shift away from vaccine support.<\/p>\n\n\n\n
Kennedy, who briefly entered the 2024 presidential race before endorsing Trump, is known for his vocal criticism of vaccines. His nonprofit organization, Children\u2019s Health Defense, has often criticized vaccines, and he has personally expressed skepticism over vaccine safety and effectiveness. Despite Kennedy\u2019s controversial stance, he attempted to allay fears in a recent NPR interview, stating, \u201cwe\u2019re not going to take vaccines away from anybody.\u201d However, this assurance has done little to mitigate market concerns, as Kennedy\u2019s longstanding position against certain vaccinations remains well-documented.<\/p>\n\n\n\n
The impact on vaccine stocks has been profound. Moderna and Novavax shares both fell over 1% in premarket trading Friday, with further after-hours declines. Investors appear wary of how Kennedy\u2019s potential leadership at HHS might shape policies related to vaccine approval, funding, and distribution, as well as broader healthcare regulations.<\/p>\n\n\n\n
For pharmaceutical companies heavily invested in vaccine research and development, Trump\u2019s appointment of Kennedy introduces a new layer of uncertainty. As the transition unfolds, market participants will likely remain cautious, watching closely for any indications of how HHS may approach vaccine and pharmaceutical regulations under Kennedy\u2019s direction.<\/p>\n\n\n\n